Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
- SK bioscience to manufacture antigen component of NVX-CoV2373
- Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373
Novavax, SK bioscience and Republic of Koreaintend to partner for manufacture and supply of vaccine for global markets including South Korea
Under the terms of the agreement, SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period.
NVX-CoV2373 was developed using
SK bioscience, using its cell culture and recombinant protein capability, will initiate the production of the NVX-CoV2373 antigen at its vaccine facility in Andong L-house,
This contract development and manufacturing organization agreement leverages the capacity reservation agreement between SK bioscience and the
This agreement further boosts the potential global supply of the NVX-CoV2373 vaccine and is an important component of Novavax’ collaboration with CEPI. Through that partnership with CEPI,
"We are proud to partner with SK bioscience to fulfill our commitment to ensure global supply of NVX-CoV2373 in alignment with our partnership with CEPI,” said
For further information, including media-ready images, b-roll, downloadable resources and more, click here.
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 data of the Phase 1/2 clinical trial, NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About SK bioscience
SK bioscience is an innovative South Korean biopharmaceutical company specialized in the vaccine area. SK bioscience developed the cell-culture based influenza vaccine named SKYCellFluTM prequalified by WHO in 2019, SKYZosterTM, the world’s second vaccine for shingles, and SKYVaricellaTM, the world’s second WHO prequalified varicella vaccine for chicken pox. By leveraging the company’s strengths on cutting-edge vaccine technologies, SK bioscience has been expanding its R&D portfolio including pneumococcal conjugate vaccine, human papillomavirus vaccine, typhoid conjugate vaccine and non-replicating rotavirus vaccine through in-house development or external partnership with public and private institutions around the globe pursuing global health. For the COVID-19 vaccine response, SK bioscience is undergoing development for its vaccine candidate against SARS-CoV-2 with support from the
Novavax Forward-Looking Statements
Statements herein relating to the future of
Brandzone/Speak Life Science
Source: Novavax, Inc.